How Sparian Biosciences’ Phase 1 launch of SBS-147 could reshape the non-opioid pain treatment landscape

Discover how Sparian Biosciences’ SBS-147 Phase 1 launch could change the race for safer non-opioid pain treatments. Read the full analysis.

Discover how Sparian Biosciences’ SBS-147 Phase 1 launch could change the race for safer non-opioid pain treatments. Read the full analysis.

Nalu’s PNS system shows 85% responder rate at 24 months. Find out what this long-term data means for neuromodulation’s future.

Soin Neuroscience and BIOTRONIK Neuro have announced a research collaboration focused on evaluating novel waveform technology and adaptive spinal cord stimulation programming aimed at enhancing chronic pain treatment outcomes. The partnership integrates proprietary signal tuning algorithms from Soin Neuroscience with the programmable Prospera SCS system developed by BIOTRONIK Neuro, reinforcing a broader industry shift toward […]